Expiration date: 09/2025
Powder lyophilized for solution preparation for infusions
1 vial contains 1 g. phosphocreatine
Neoton - a drug that improves myocardial metabolism and muscle tissue. On chemical structure similar makroergicheskih endogenous phosphocreatine. Slows down the process of destruction of the sarcolemma of ischemic cardiomyocytes and myocytes, provides intracellular transport of energy. By improving microcirculation drug reduces the size of the zone of necrosis and ischemia. During ischemia and postischemic reperfusion causes antiarrhythmic effect, which is associated with a decrease in ectopic activity of the ventricles and preservation of physiological functions of the cells of the Purkinje fibers.
- acute myocardial infarction,
- chronic heart failure,
- intraoperative myocardial ischemia,
- intraoperative ischemia of the extremities,
- acute violation of cerebral circulation,
- sports medicine: prevention of development of a syndrome of physical stress and improving adaptation to extreme physical stress.
Hypersensitivity to the drug.
Application of pregnancy and breastfeeding
Data on the safety and efficacy of Neoton during pregnancy and lactation (breastfeeding) not available.
Method of application and doses
In acute myocardial infarction in the 1st day administered 2-4 g/per jet, followed by drip infusion of 8 to 16 g in 200 ml 5% glucose solution for 2 h on the 2nd day administered 2-4 g/drip 2 times/day. In 3 days administered 2 g/drip 2 times/day.
If necessary, infusion of the drug at 2 g 2 times/day can be carried out within 6 days.
In chronic heart failure give/drip in 1-2 g 2 times/day for 10-14 days.
Intraoperative myocardial ischemia, the drug is administered as part of a conventional cardioplegic solution in an amount of 3 g per 1 liter. Neoton added to the composition of the solution immediately before administration. Recommended rate of infusion of the drug at 2 g, 2 times/day for 3-5 days prior to surgery and for 1-2 days after surgery.
If possible, the development of intraoperative ischemia of the extremities is recommended in bolus to enter 2-4 g of the drug before surgery, followed by infusion of 8-10 g in 5% glucose solution during the operation and the period of reperfusion.
The drug should be administered in the shortest possible time from the time of onset of ischemia, providing a more favorable prognosis.
Neoton is not used for emergency correction of disorders of the heart.
When used in the complex therapy Neoton enhances the effectiveness of antiarrhythmic, antianginal drugs and drugs that have a positive effect on the inotropic function of the myocardium.
The drug should be stored at room temperature.